Based: San Diego
Raised: $50 million
Investors: Leucadia National

The scoop: Sangart reaped $50 million in equity funding from its existing investor, Leucadia National, boosting its total funding raised to more than $280 million. The latest round, which was finalized in May, provides fuel for the development of the San Diego-based biotech's drugs, which deliver "essential gases to embattled tissues." The fresh infusion arrived after an independent committee gave its thumb's up for investigators to pursue an ongoing mid-stage trial of MP4OX, designed to treat tissues threatened with ischemia following hemorrhagic shock. "We continue to see promise in our unique MP4 gas-delivery platform, focused on developing therapies for patients in crisis who are experiencing ischemia and organ dysfunction as a result of hemorrhagic shock injury or a vaso-occlusive crisis associated with sickle cell disease," Sangart CEO Brian O'Callaghan said last May. 



Suggested Articles

Dr. Ian Hudson is stepping down after six years in charge of the Medicines and Healthcare products Regulatory Agency next month.

Finch thinks it has a shot at winning FDA approval of the full-spectrum microbiota drug if the ongoing clinical study generates “compelling results.”

Chinook Therapeutics raised $65 million to do for kidney disease what precision medicine has done for cancer. It aims to be in the clinic by 2021.